Biomarkers for Cognitive Decline in Intracerebral Hemorrhage
The goal of this clinical trial is to see if silent brain infarcts (SBIs), or stroke-like symptoms detectable during brain imaging, are a possible contributor to cognitive decline for patients diagnosed with spontaneous intracerebral hemorrhage (sICH), or blood clot in the brain. The main questions it aims to answer ar
| Condition(s) | Primary Intracerebral Hemorrhage |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The goal of this clinical trial is to see if silent brain infarcts (SBIs), or stroke-like symptoms detectable during brain imaging, are a possible contributor to cognitive decline for patients diagnosed with spontaneous intracerebral hemorrhage (sICH), or blood clot in the brain. The main questions it aims to answer are * if SBIs in sICH are associated with a lower cognitive level and more rapid cognitive decline * if SBIs in sICH are associated with certain findings on brain imaging * if SBIs in sICH are associated with higher inflammation measured by certain blood tests Participants will undergo * cognitive testing during hospitalization, and at 3, 6 and 12 months after the sICH * Magnetic Resonance Imaging (MRI) of the brain during hospitalization and 12 months after the sICH * blood dr |
| Who can participate | Inclusion Criteria: * Primary Intracerebral Hemorrhage * Age ≥ 18 and \< 80 years Exclusion Criteria: * ICH score \> 2 * Pre-existing dementia * Prior history of stroke * Neurosurgical evacuation of hematoma |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | Rush University Medical Center |
| Locations | Chicago, Illinois, United States |
| Start date | 2025-08-02 |
| NCT ID | NCT06836141 |
| Official listing | https://clinicaltrials.gov/study/NCT06836141 |